Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
parkin activators
- Development stage
- Preclinical
- Lead developer
- Nine Square Therapeutics
- Modality
- Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Administration
- Oral
01
Overview
Parkin activators are a class of small molecule allosteric modulators being developed by Nine Square Therapeutics for the treatment of Parkinson's disease and metabolic disorders. These compounds act as molecular glues that enhance the interaction between phospho-ubiquitin (pUb) and the E3 ubiquitin ligase Parkin (PRKN). By promoting Parkin's activity, these activators facilitate mitophagy—the selective degradation of damaged mitochondria—thereby restoring cellular mitochondrial function and providing neuroprotection to dopaminergic neurons. The program is currently in preclinical development and has received significant research funding from the Michael J. Fox Foundation.
- Other names
- PRKN activatorsParkin RBR E3 ubiquitin protein ligase activators
02
Targets
PRKN (E3 ubiquitin-protein ligase parkin)
Beyond the preview
Go deeper on parkin activators.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on parkin activators.